28 results about "C57BL/6" patented technology

The present application provides a mouse model for studying microsatellite stable and unstable intestinal cancer. Specifically, the present application provides the use of a hybrid mouse in a reagent or kit for preparing a mouse model animal for constructing MSS type intestinal cancer and MSI-H type intestinal cancer, wherein the mouse is a F1 generation of C57BL / 6 x BALB / c. The mouse model of the present application provides the same genetic background for MSS type intestinal cancer cells and MSI-H type intestinal cancer cells, making the research of MSS type intestinal cancer and MSI-H type intestinal cancer more scientific.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application belongs to the technical field of biotechnology, and particularly relates to a colorectal cancer high liver metastasis cell line and a preparation method and application thereof. The cell line was preserved in the China Center for Type Culture Collection on January 14, 2026, and the preservation number is CCTCC NO: C202618. The cell line is derived from a mouse colorectal cancer cell line MC38, and is constructed by lentivirus transfection to express luciferase stably, and is obtained by continuously performing at least five rounds of liver metastasis tumor orthotopic iteration screening in C57BL / 6 mice through rectal submucosal injection. The MC38-P06 cell line provided by the application has a significantly enhanced liver metastasis ability, a shorter MC38-P01 model time, a higher liver tumor load, and a shorter mouse survival period, and can be used for screening and evaluating anti-liver metastasis drugs, researching liver microenvironment regulation mechanisms, and identifying liver metastasis related diagnostic markers.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention relates to the technical field of bioengineering, and particularly discloses a construction method and application of a mixed type liver cancer mouse model, pCMV-Cre, pT3-EF1 alphaH-c-Met, pT3-EF1 alphaH-N90-beta-catenin plasmids and pCMV (CAT) T7-SB100 transposase are mixed to prepare an injection, and the injection is injected into a C57BL / 6-MFN1flox / flox mouse at the age of 6 weeks in a caudal vein mode to obtain the mixed type liver cancer mouse model. The construction method of the mixed type liver cancer mouse model is stable, reliable, efficient and easy to implement, and the constructed mixed type liver cancer mouse model can be used for exploring the generation and development mechanism of the mixed type liver cancer and researching treatment targets and can also be used for screening drugs for treating the mixed type liver cancer.

The invention discloses a CAR-T cell for overexpressing H2A. Z as well as a preparation method and application of the CAR-T cell. In particular, the present invention provides a chimeric antigen receptor comprising an H2A. Z gene or a variant having the same function as the H2A. Z gene. The chimeric antigen receptor further comprises a signal peptide, a CLDN18.2-targeted antigen binding structural domain, a hinge region, a transmembrane region, a co-stimulation structural domain and an intracellular signal transduction structural domain. In a C57BL / 6 mouse model inoculated with CLDN18.2 positive tumor cells MC38-CLDN18.2 and KPC, the treatment effect of the CLDN18.2-CAR-T cell for overexpressing the H2AZ.1 gene disclosed by the invention is obviously superior to that of a CLDN18.2-CAR-T control group without overexpressing the H2AZ.1 gene.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The invention provides a lung cancer cell LLC-ML2 as well as an establishment method and application thereof. The lung cancer cells are used for highly expressing CD18 molecules, Strc molecules, Cd79a molecules, Amigo2 molecules, Plet1 molecules, Angptl4 molecules and Plac1 molecules; ddx3y, Cbr3, Sox11, Pid1, Kdm5d, Eif2s3y and Capn6 molecules are not expressed or are subjected to low expression. The LLC cell strain is obtained by inoculating common LLC cells to a C57BL / 6 mouse, taking a lung metastatic focus for culture, inoculating primarily cultured metastatic focus cells to the C57BL / 6 again, taking the lung metastatic focus for different clone culture, and screening. Through two times of lung metastatic focus tumorigenesis and screening, compared with LLC cells, the lung cancer cells are shorter in use time for constructing a metastasis model, and the metastasis rate of main organs is higher; an efficient cell model is provided for better researching a tumor invasion and metastasis mechanism.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a stable and high-reproducibility severe acute pancreatitis mouse model construction method, a quantitative evaluation system and application thereof, and the method comprises the following steps: selecting a male C57BL / 6 mouse of 6-8 weeks old, adaptively feeding for one week, and then carrying out model induction; the preparation method comprises the following steps: carrying out intraperitoneal injection on leptofrog at the dosage of 100 mu g / kg once every 1 hour, and continuously injecting for 7 times; within 2 hours after completion of the seventh time of rain frog element injection, lipopolysaccharide is injected into the abdominal cavity, and the dosage is 12 mg / kg; pathological and physiological index evaluation is carried out on the mouse 24 hours after the first time of rain frog element injection, and multi-batch verification experiments prove that the inter-batch fluctuation range of the model constructed by the invention on the death rate, the pathological score, the weight change and other key indexes is controlled within + / -5%, so that the repeatability and comparability of experimental results are ensured.

The application provides a construction method and application of a preeclampsia animal model, and belongs to the technical field of construction of animal models. The construction method of the preeclampsia animal model provided by the application comprises the following steps: during pregnancy of a female mouse, phthalic acid or an adenovirus is given to inhibit activity of QPRT, and thus the preeclampsia animal model is obtained. The female mouse is a 8-week-old female C57BL / 6 mouse, the female mouse is given the phthalic acid or the adenovirus at the 10.5th day or the 16.5th day of pregnancy, the dosage of the phthalic acid is 50 mg / kg, the dosage of the adenovirus is 10 9 copies / ml. The construction method of the animal model provided by the application has the advantages of simple operation, the drug can be concentrated in the local maternal-fetal interface to play a role by the drug administration mode of uterine cavity perfusion, and the construction method can eliminate the whole-body symptoms caused by intraperitoneal injection and intravenous injection; and the mouse model can better simulate the clinical symptoms and indexes of patients with preeclampsia, and provides a new mouse model for research on the pathogenesis of preeclampsia.

The twitcher mouse model is a main animal model for researching the pathogenesis and treatment method of GLD disease at present, and the model is caused by a spontaneous mutation of a C57BL / 6 mouse model GALC At present, a commonly used genotype identification method is time-consuming and expensive. In order to overcome the defect, the special identification primer is designed, the PCR method is adopted, and the restriction endonuclease Eco RV is used for single enzyme digestion verification, so that a rapid, efficient and economic genotype identification method is established, and a reference for the genotype identification of the twitcher mouse is provided.

The application discloses a macrocyclic naphthalene sulfonamide derivative or a pharmaceutical salt thereof, and a structure general formula is as follows: The macrocyclic naphthalene sulfonamide derivative or the pharmaceutical salt thereof has a protective effect on an LPS-induced BV2 cell inflammation model as a Keap1-Nrf2 protein interaction inhibitor, and has a preventive and therapeutic effect on CUMS modeling C57BL / 6 mouse depression.

The invention belongs to the technical field of construction of cell models, and particularly relates to a method for constructing a hyperuricemia testicular interstitial cell model. Comprising the following steps: (1) selecting an 8-week-old male C57BL / 6 mouse, dissecting, collecting testis, removing testis albuginea, cutting into fragments, digesting by utilizing collagenase IV, filtering, centrifuging, discarding supernatant, diluting cell suspension, adding luteinizing hormone receptor coupled fluorescein to mark testis interstitial cells, and sorting by utilizing flow cytometry to obtain testis interstitial cell suspension; (2) counting by using a blood cell counting plate, diluting the testicular interstitial cells, inoculating the testicular interstitial cells into a 24-pore plate, and culturing the testicular interstitial cells in a cell culture box; and (3) after 24-48 hours, taking out the 24-well plate, discarding cell supernate, cleaning with PBS, adding a uric acid solution, and continuously culturing to obtain the hyperuricemia testicular interstitial cell model. The obtained interstitial cell model can be used for exploring various function change mechanisms of the testicular interstitial cells in a hyperuricemia environment, and is simple to operate, effective, high in repeatability and short in time consumption.

The invention discloses a traditional Chinese medicine cold-heat property evaluation method based on small animal metabolism analysis and body temperature monitoring, and belongs to the technical field of traditional Chinese medicine modernization evaluation. A C57BL / 6 mouse is used as a model, a small animal energy metabolism monitoring system is used for continuously collecting metabolic indexes of the mouse, and the metabolic indexes are compared with a blank control group according to the metabolic indexes, so that the cold-heat property of the traditional Chinese medicine is objectively judged. The influence of the processing technology on the medicine property is further evaluated by comparing the metabolic indexes of the same crude traditional Chinese medicine product and the processed product. In order to improve the discrimination reliability, multi-modal data fusion discrimination can be carried out in combination with a body temperature change index measured on a cold / heat syndrome model animal. The invention provides a rapid, quantitative and repeatable traditional Chinese medicine property evaluation scheme.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of a drug for treating sarcopenia, wherein the traditional Chinese medicine composition consists of Astragalus membranaceus and Anemarrhena asphodeloides. The study found that the combination of Astragalus membranaceus and Anemarrhena asphodeloides can significantly improve the differentiation function of C2C12 myoblasts induced by high glucose and inhibit lipid deposition, and improve skeletal muscle mass, muscle strength, and motor function in a streptozotocin-induced C57BL / 6 diabetic sarcopenia mouse model. In vitro and in vivo experiments have confirmed that this drug has significant effects in improving muscle atrophy, enhancing motor function, and restoring muscle strength; it can effectively increase the cross-sectional area of ​​muscle fibers, promote myotube fusion, and accelerate damage repair, showing a clear potential to inhibit diabetic muscle atrophy. This provides an effective traditional Chinese medicine compound intervention strategy for the clinical treatment of diabetic sarcopenia and has good prospects for development and application.

The invention relates to a systemic lupus erythematosus animal model and a construction method and application thereof, and belongs to the technical field of disease animal model construction methods. The animal model construction method for systemic lupus erythematosus comprises the following steps: hybridizing a female mouse of a C57BL / 6 strain as a female parent with a male mouse of an SJL / J strain as a male parent to generate an F1-generation hybrid mouse, and the F1-generation hybrid mouse is more likely to have a lupus phenotype. Compared with a C57BL / 6 female parent, the animal model for systemic lupus erythematosus, provided by the invention, can develop typical symptoms of lupus more quickly and more remarkably, so that the experimental period is greatly shortened, and the research efficiency is improved. Based on the C57BL / 6 background, subsequent fine genetics and mechanism research is facilitated. The method can be obtained through traditional breeding without complex gene operation, is good in stability and high in repeatability, and provides an efficient and reliable new tool for lupus research.

The invention discloses application of sinapine thiocyanate in preparation of a medicine for treating lung cancer, and relates to the technical field of medicines. Specifically, the invention provides application of sinapine thiocyanate in preparation of drugs for treating lung cancer, and the lung cancer is non-small cell lung cancer. It is revealed that sinapine thiocyanate reduces infiltration of tumor-related macrophages and myeloid-derived suppressor cells in tumors by improving infiltration of CD4 + T cells, CD8 + T cells and M1 type macrophages in the tumors, remarkably inhibits growth of the tumors in C57BL / 6 mouse lung cancer transplanted tumors, has an immunoregulation effect and does not have obvious liver and kidney toxicity; by inhibiting expression of HIF-1alpha, PKM2, HK2 and LDHA, aerobic glycolysis of tumor cells and secretion of lactic acid are inhibited, so that sinapine thiocyanate has a good application prospect in medicines for treating lung cancer.

The invention relates to the technical field of model animal preparation, in particular to a construction method of a congenital dilated cardiomyopathy animal model, which comprises the following steps: parent animal screening and pretreatment: selecting 8-week-old SPF-grade C57BL / 6 mice, placing the mice in an SPF-grade animal house, and adaptively feeding the mice for 1 week; benzopyrene exposure treatment: from the first day of cage closing to the end of the lactation period, a benzopyrene solution is administered to the female rats in a nasal instillation mode every day, and the dosage is 1 mg / kg; after natural delivery of the pregnant rats, the offspring mice are lactated from the female rats to 21-day-old weaning, and then standard feed is adopted for free ingestion and water drinking; and performing model phenotype verification: performing verification when the offspring mice are 8 weeks old, 12 weeks old, 16 weeks old, 20 weeks old and 24 weeks old respectively, and screening out animal models conforming to the characteristics of the congenital dilated cardiomyopathy. The construction method of the congenital dilated cardiomyopathy animal model can simulate the clinical characteristics of development origin-latency-delayed onset-progression of the disease, and the model is high in stability and specificity.

The invention discloses an application of an AgrJ inhibitor in preparation of a drug for resisting pseudomonas aeruginosa infection. Experiments prove that the P.aeruginosa ArgJ is a gene for inhibiting the pyroptosis of host cells, and in an in-vitro macrophage and in-vivo C57BL / 6 mouse infection model, the ArgJ is found to remarkably promote the intracellular and in-vivo survival of the P.aeruginosa. The discovery not only deepens the understanding of infection pathogenesis, but also verifies the feasibility of targeting ArgJ as a brand new treatment strategy, and provides an original theoretical basis and a potential target for the research and development of anti-pseudomonas aeruginosa drugs.

The invention belongs to the technical field of pharmacy, and discloses application of chelidonic acid in preparation of a medicine for treating fungal keratitis. The invention provides that chelidonic acid can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a C57BL / 6 mouse is adopted to establish a fungal keratitis model, and the influence of chelidonic acid on the corneal clinical score of the model mouse, the recruitment of neutrophil and macrophage, the corneal fungal load and the expression of IL-1beta, IL-6, TNF-alpha, MyD88 and NF-kappa B is researched. In in-vitro experiments, it is studied that chelidonium acid with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an RAW264.7 cell model stimulated by aspergillus fumigatus is adopted to verify the influence of chelidonium acid on a MyD88 / NF-kappa B signal channel.

The invention discloses application of a gingko armillaria mellea oral solution in preparation of a medicine for preventing and treating inflammatory bowel diseases. Through a prevention and treatment test of the ginkgo armillaria mellea oral solution on mouse ulcerative colitis, a C57BL / 6 mouse DSS induction method is adopted to construct a model, and the effect of 390mg / kg and 780mg / kg of the ginkgo armillaria mellea oral solution on resisting mouse inflammatory bowel diseases is evaluated. The result shows that the gingko armillaria mellea oral solution can obviously improve the mouse hematochezia condition; the colon length is increased, the colon weight / length ratio is reduced, and colonic mucosa hyperemia is reduced; the weight is increased. Therefore, the gingko armillaria mellea oral solution has the characteristics of high efficiency and low toxicity for preventing and / or treating inflammatory bowel diseases.

The invention belongs to the technical field of pharmacy, and discloses application of physcion in preparation of a medicine for treating fungal keratitis. The invention proposes that the physcion can inhibit the growth of corneal fungi for the first time, and has a treatment effect on fungal keratitis under in-vivo and in-vitro conditions. In an in-vivo experiment, a fungal keratitis model is established by adopting a C57BL / 6 mouse, and the influence of the physcion on the corneal clinical score of the model mouse, the recruitment of macrophages and neutrophils and the expression of NF-kB and interleukin 1beta is researched. In-vitro experiments prove that emodin monomethyl ether with different concentrations has an inhibiting effect on growth of aspergillus fumigatus, and meanwhile, an aspergillus fumigatus stimulated mouse macrophage model verifies the influence of emodin monomethyl ether on an NF-kB / IL-1beta signal channel.

This invention belongs to the field of traditional Chinese medicine and discloses the application of total saponin extracts from *Abrus precatorius* in the preparation of drugs for treating and preventing liver injury caused by immune checkpoint inhibitors. This invention is the first to use total saponins from *Abrus precatorius* for preventative treatment of liver injury caused by immunosuppressants and has demonstrated significant efficacy. After preventative treatment with total saponins from *Abrus precatorius*, liver injury caused by immunosuppressants was significantly alleviated in Pdcd1 knockout C57BL / 6 mice, with a significant decrease in ALT and AST levels and a significant reduction in hepatic immune infiltration. Furthermore, transcriptome sequencing analysis showed that total saponins from *Abrus precatorius* mainly exert their pharmacological effects by inhibiting the activation of the cGAS-STING pathway, indicating that preventative administration of total saponins from *Abrus precatorius* can alleviate the pathological state and inflammatory level of ICI liver injury, thus showing promise for practical application.

The invention discloses lactobacillus rhamnosus with an effect of preventing helicobacter pylori infection and application of the lactobacillus rhamnosus, and belongs to the technical field of biological medicines and microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 21, 2025, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. 34273. The JGSLR02 is a lactobacillus rhamnosus strain with excellent probiotic characteristics, and especially has excellent helicobacter pylori antagonism potential in vitro. A helicobacter pylori infected C57BL / 6 mouse model proves that the rhamnosus lactobacillus has the capability of preventing occurrence and development of mouse helicobacter pylori infection, and can antagonize helicobacter pylori in vivo, prevent helicobacter pylori infection, relieve inflammatory response and promote gastric mucosa repair.

The present application belongs to the field of animal models, and particularly relates to a construction method and application of an environmental stress source heart failure animal model. The method is as follows: 4-6 week old C57BL / 6 mice are continuously given a mixed heavy metal solution containing lead, mercury and cadmium in the form of free drinking water every day, and when the left ventricular ejection fraction is less than 50%, an environmental stress source heart failure mouse model is obtained. From the perspective of simulating the combined exposure of various heavy metals in the real environment, the present application constructs an animal model highly consistent with the characteristics of clinical heart failure. The modeling method of the present application is simple, and the stability of indexes such as ejection fraction, fractional shortening and BNP in the model is good, the repeatability is strong, the method is reliable, the modeling rate is high, and the model constructed can be used in the fields of exploring the mechanism and molecular target of heart failure, screening drugs for treating heart failure or environmental toxicant evaluation.

The invention relates to a method for constructing a non-alcoholic steatohepatitis mouse model. The method sequentially comprises the following steps that SPF-level C57BL / 6 male mice are divided into a model group and a control group after a standard feed and drinking adaptive period for one week; the model group is fed with high-fat and high-cholesterol diet, sweet water is given, CCl4 injection is carried out once a week, and standard feed and drinking water are given to the control group; monitoring fasting weight every week; in the fourth week and the twelfth week, the mouse is killed, livers are collected and weighed, tissue slices are prepared, oil red O, sirius red and HE staining analysis is conducted, and then evaluation analysis is conducted. The method provided by the invention overcomes the limitation of the existing model, and also provides support for the research of NASH etiology and the development of new drugs.